Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or“Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced the company’s new research data of its oncology program D3S-001 has been presented at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Those data highlight D3 Bio’s pipeline innovations in cancer treatment.
Title: Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics
D3S-001 is a small molecule inhibitor that selectively and irreversibly inhibits the KRAS G12C mutant protein, blocking its interaction with downstream effectors, such as the RAF serine/threonine protein-kinase, thereby preventing the propagation of oncogenic signaling. D3S-001 is currently in phase 1 clinical development globally.
D3 Bio is a globally orientated, clinical stage biotechnology company that focuses on discovery, development and registration of new medicines in oncology and immunology. At D3 Bio, we fully leverage our clinical insight and biomarker strategy to guide our discovery effort and compound development, aiming to create novel and clinically meaningful new therapies for patients in need.
D3 Bio is funded by globally renowned investors, including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXiAppTec's Corporate Venture Fund.
For inquiries, please contact: